Skip to main content

Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature

Abstract

Background

SARS-CoV2 virus could be potentially myopathic. Serum creatinine phosphokinase (CPK) is frequently found elevated in severe SARS-CoV2 infection, which indicates skeletal muscle damage precipitating limb weakness or even ventilatory failure.

Case presentation

We addressed such a patient in his forties presented with features of severe SARS-CoV2 pneumonia and high serum CPK. He developed severe sepsis and acute respiratory distress syndrome (ARDS) and received intravenous high dose corticosteroid and tocilizumab to counter SARS-CoV2 associated cytokine surge. After 10 days of mechanical ventilation (MV), weaning was unsuccessful albeit apparently clear lung fields, having additionally severe and symmetric limb muscle weakness. Ancillary investigations in addition with serum CPK, including electromyogram, muscle biopsy, and muscle magnetic resonance imaging (MRI) suggested acute myopathy possibly due to skeletal myositis.

Conclusion

We wish to stress that myopathogenic medication in SARS-CoV2 pneumonia should be used with caution. Additionally, serum CPK could be a potential marker to predict respiratory failure in SARS-CoV2 pneumonia as skeletal myopathy affecting chest muscles may contribute ventilatory failure on top of oxygenation failure due to SARS-CoV2 pneumonia.

Background

Swarming spread of SARS-CoV2 pandemic revealed substantial and varied neuromuscular manifestations [1]. Recent data from Wuhan, China, suggest that neurological symptoms/signs are present in over 30% of patients with severe SARS-CoV2 infection [1]. It spans from involvement of the central to the peripheral nervous system manifesting as headache, dizziness, encephalopathy, epileptic seizures, and stroke or muscle weakness. This involvement indicates its affinity toward different levels of nervous system or the effector tissues like skeletal muscle or sensory receptor organs. Neurotropism of this virus is apparent from the evidence of impairment of test and/or smell sensation early in the course of illness, which specifies its affection toward gustatory or olfactory sensory nerve terminals. The virus is also isolated from the cerebrospinal fluid suggesting potential neuroinvasive nature of SARS-CoV2. Involvement of the peripheral nerves was claimed to have association with SARS-CoV2 infection resulting in Guillain-Barré syndrome (GBS). On the other hand, skeletal muscle damage due to SARS-CoV2 infection has been highlighted in several reports documenting nearly 23% of severe infection [1,2,3]. Importantly, weakness due to severe myopathy can adversely affect the outcome in SARS-CoV2 pneumonia. Recently acute severe myopathic weakness has been documented in six patients in severe SARS-CoV2 pneumonia requiring mechanical ventilation [3], however the mechanism of skeletal muscle damage remained elusive. Our patient may in part address the pathogenesis of myopathy in SARS-CoV2 infection.

Case presentation

A 42-year-hypertensive man having history of bronchial asthma presented with high-grade continuous fever, dry cough, and sore throat. He was brought to hospital for difficulty in breathing, experienced on day 5 of his febrile illness. On admission, he looked toxic, febrile (103 °F) and tachypnoeic (40 breaths/min) with low peripheral SpO2 (85%). He was hypotensive (90/40 mm Hg) having a rapid pulse (120/min). Wheeze and crackles were obvious on chest auscultation especially on mid and lower zones of both lung fields along with woody dull percussion note in the abovementioned areas. This suggested severe SARS-CoV2 pneumonia. He was immediately shifted to intensive care unit (ICU) addressing the severity of chest infection and need for respiratory assistance. High flow oxygen was given through nasal canula, intravenous fluid, and ceftriaxone 1g bd were administered and necessary investigations were sent including deep nasopharyngeal swab for PCR for SARS-CoV2. Inspite of receiving high flow oxygen, due to relentless desaturation of peripheral SpO2, he was orotracheally intubated for assisted mechanical ventilation. His peripheral blood picture showed high total leukocyte count with neutrophilic leukocytosis, elevated serum C-reactive protein, procalcitonin, ferritin, and serum CPK (Table 1). Chest X-ray showed bilateral bronchopneumonic patchy opacities but serum troponin, serum pro-BNP, and echocardiogram was within normal range. He was PCR positive for SARS-CoV2 and received intravenous remdesivir (100 mg daily for 10 days), tocilizumab (8 mg/kg; 2 doses), and dexamethasone (5 mg q6h for 5 days and 5 mg bd for 7 days). Otherwise, in favor, he had intact orientation and his hemoglobin level, coagulation profile (platelet count, PT, and APTT), serum electrolytes, serum anti-GM1 antibody titer and blood sugar level were within normal limits and he had preserved liver and renal functions (Table 1). However, his serum d-dimer was elevated. Subsequently, high resolution spiral CT scan of chest revealed bilateral diffuse ground glass densities and reticulation with features of consolidation and sub-segmental pulmonary embolism. Accordingly, he received subcutaneous low molecular weight heparin for 2 weeks from the second day of his ICU admission. In view of high CRP, increasing O2 requirement and inability to sustain a stable blood pressure, tracheal aspirate, blood and urine samples were sent for culture and sensitivity (CS) on the 3rd day of admission to exclude secondary bacterial infection. Ceftriaxone was changed to intravenous teicoplanin (for 10 days) for a broader antibacterial coverage. Tracheal aspirate CS revealed growth of methicillin-resistant Staphylococcus aureus (MRSA), which was fortunately sensitive to teicoplanin. He required sedation (intravenous midazolam and fentanyl for 10 days) and muscle relaxation (IV vecuronium for 2 days) to maximize the tolerability of mechanical ventilation. On the 10th day of his mechanical ventilation, when sedation was gradually withdrawn, weaning from ventilator was unsuccessful and marked symmetrical upper and lower limb weakness was apparent. Both his upper and lower limbs were paralyzed (power 0/5), moderately wasted, flabby, and deep tendon reflexes could not be elicited with an intact sensation in all modalities. However, he was fully alert, and functions of all cranial nerves were preserved. At this time, serum CPK was higher (1325 mcg/mL) than at admission (850 mcg/mL). Electrophysiology done on day 20 of admission revealed normal motor and sensory conduction but myopathic changes on needle electromyogram (EMG) examination, consisting of spontaneous muscle fiber activity, small motor unit potentials, and a full recruitment pattern (Fig. 1). Thigh and calf muscle MRI done on day 20, showed marked hyperintensity in both the quadriceps muscles (Fig. 2e), mild hyperintensity in the hamstrings, and patchy hyperintensity in the leg muscles. Skeletal muscle histopathology done on day 23 and muscle sections sampled from quadriceps femoris showed variation in muscle fiber size with predominantly spherical shape myosites and multifocal and discrete myosite degeneration lacking infiltration of inflammatory cells (Fig. 2a-d). Other specific histopathologic or histochemical analyses could not be done. Eventually, he could be weaned from respirator and maintain SpO2 with ambient air at day 18 from the day of intubation. He was mechanically ventilated with control/assist control mode ventilation for the 1st 2 days and then put onto synchronized intermittent mandatory ventilation (SIMV) mode for 12 days and was on only pressure support ventilation (PSV) for the last 4 days using continuous positive airway pressure (CPAP) mode ventilation.

Table 1 Laboratory investigation findings of the presented case with acute myopathy following SARS-CoV2 infection
Fig. 1
figure1

Nerve conduction study, electromyogram, and disease trajectory. (a) Motor and sensory nerve conduction was normal despite severe muscle weakness. Compound muscle action potential (CMAP) amplitudes are measured in millivolts (mV); 2 mV per division for all motor study traces. DML, distal motor latency in ms. MCV1, motor conduction velocity in millisecond (ms). MCV2, motor conduction velocity in ms. Sensory nerve action potential (SNAP) amplitudes are measured in microvolts (μV); 20 μV per division for all sensory study traces. DSL, distal sensory latency. SCV, sensory conduction velocity. (b) Electromyogram (EMG) showing myopathic motor unit potentials, a full recruitment pattern and spontaneous muscle fiber activity in several sampled muscles. Motor unit potential (MUP) amplitudes are measured in microvolt (μV); 200 μV per division for all EMG traces

Fig. 2
figure2

Muscle histopathology and MRI of upper thigh axial sections. (a-d) Muscle histopathology sections sampled from quadriceps femoris muscle stained with hematoxylin and eosin, showed variation in muscle fiber size with predominantly spherical shape myosites and multifocal and discrete myosite degeneration lacking infiltration of inflammatory cells. (e) T2 weighted MRI section of the upper thigh done on day 20, showed marked hyperintensity in both the quadriceps muscles. (f) Repeat T2-weighted MRI of the same section of the thigh muscles done after 48 days of the 1st MRI shows both the quadriceps muscles appear normal

He became SARS-CoV2 negative on repeat PCR on day 15 of his onset of weakness. Improvement of his limb muscles showed fair progress (muscle power: distal= 4/5 and proximal= 3/5) when he was discharged from hospital after 4 weeks of his hospital stay. His muscle power was normalized 1 month after his discharge from hospital. At this time, his serum CPK, d-dimer, and serum ferritin were within normal limit and a repeat MRI of his lower limb muscles appeared almost normal (Fig. 2f).

Discussion and conclusions

Severe acute myopathy can be a life-threatening complication in SARS-CoV2 infection. Our patient presented with SARS-CoV2 pneumonia complicated to acute respiratory distress syndrome (ARDS) and eventually developed features of severe myopathy in quick succession. However, serum CPK was already elevated on admission suggesting the particular potential to damage the skeletal muscle tissue from the beginning of illness. Throughout the illness, except severe pneumonia, sepsis, and skeletal muscle damage, other major organ functions were stable. SARS CoV’s predilection for the skeletal muscle was known from the pandemic that broke in March 2003 [4, 5]. At that time, in addition to lung damage, muscle weakness and elevation of serum CPK level was documented in more than 30% of the SARS-infected patients [6]. Similar myopathogenic potential has also been documented currently in around 20% severe SARS-CoV2 infection [1]. However, the pathogenesis of muscle damage still remains unknown.

A series of six cases with acute myopathy has recently been published from Italy [3]. All the cases in the Italian series showed marked prolongation of motor nerve distal Compound Muscle Action Potential (dCMAP) duration, which was absent in our case. Prolongation of dCMAP indicates distal motor nerve myelin damage, frequently present in demyelinating GBS. Terminal motor axons are vulnerable to immune-mediated attack because here the blood nerve barrier is deficient and axons become unmyelinated just before they join the myoneural junction. Therefore, immune mediated or direct viral invasion at the nerve terminals could be a possibility of paranodal disruption resulting features of distal demyelination. However, evidence goes in favor of indirect muscle injury, as viral particles could not be isolated from damaged skeletal muscle tissues of the patients infected with SARS-CoV [4]. Additionally, prolongation of dCMAP has also been documented in some cases of critical care myopathy, postulated slowing of the muscle fiber conduction velocity, and reduced sarcolemmal excitability [7].

Our patient presented with rapidly progressing symmetrical quadriplagia and loss of deep tendon reflexes. We assumed the possibility of Guillain-Barré syndrome (GBS), which has been documented to be associated with SARS-CoV2 infection in recent literatures [8,9,10]. Based on our interpretation, this association of GBS and SARS-CoV2 infection could be co-incidental as sufficient epidemiological evidence is lacking which was very obvious between GBS and Zika virus infection in recent past [11]. Our clinical suspicion of GBS was also doubted, as despite having marked muscle weakness, our patient did not have any cranial nerve deficits, elevated serum CPK, and cerebrospinal fluid assessment did not reveal albuminocytological dissociation. Evaluation of serum anti-GM1 antibody was within normal limit, which is a potential marker for pure motor AMAN variant of GBS, prevalent in Bangladesh [12]. Eventually, electrophysiology suggested myopathic involvement. We admit that ARDS, severe sepsis, and potentially myopathogenic medications like corticosteroids and muscle relaxants that had been used in the ICU could possibly trigger critical illness polyneuropathy/myopathy (CIP/CIM) [13] and in part may contribute in the disease process. However, muscle relaxant was used for only 2 days and serum CPK was already high at admission when none of these medications were used. Moreover, in critical care, myopathy raised serum CPK is not common. In light of recent evidence on CIP/CIM animal model, steroid may not be substantially contributing to CIM [14, 15]. MRI of the pelvis and lower limb muscles clearly showed hyperintensity in both quadriceps and leg muscles suggestive of myositis. However, muscle histopathology showed multifocal and discrete myosite degeneration without infiltration of inflammatory cells suggesting noninflammatory pathology. However, role of neucleotide analog antiviral drug remdicivir and anti-IL6 antibody tocilizumab were unlikely to contribute in the process of weakness but they might influence the muscle biopsy findings specially extinguishing inflammatory evidences where corticosteroids could also had a substantial role. These muscle histopathology features are nonspecific and similar to CIM or viral myositis found in influenza B. But infectious nature of myositis was established as influenza B virus could be isolated from skeletal muscle tissue [16]. Importantly, even in the past, neither muscle inflammation nor SARS-CoV could not be isolated from cadaveric skeletal muscle tissue from confirmed SARS-CoV infected patients with features of severe myopathy, suggesting CIM, or indirect myotoxic effect of this virus [4]. This is acknowledged that Th1 cell-mediated cytokines can produce inflammatory response in muscle tissue [17]. Interestingly, cytokine storm in SARS-CoV2 is also Th1 driven, that can induce muscle inflammation [18].

We admit, due to limited laboratory facilities, we could not explore further to identify the cause of this skeletal myopathy. Since thick filament myopathy is the commonest form of CIM, assessment of the content of myosin in relation to actin in the skeletal muscle tissue through electrophoretic separation could help a step forward to ascertain this type of myopathy with more precision.

Although we were not able to determine whether our patient had CIM or SARS-CoV2 associated myopathy, the following arguments are in favor of CIM: (i) an episode of ARDS requiring prolonged mechanical ventilation, (ii) use of myopathogenic medication like muscle relaxants and corticosteroids. On the other hand, SARS-CoV2-associated myopathy is favored by (i) presence of high serum CPK before the onset of mechanical ventilation, (ii) the fact that high serum CPK is unusual in CIM [19, 20], (iii) the remarkable synchronicity of myopathy and SARS-CoV2 infection, (iv) muscle MRI imaging compatible with myositis, (v) the similarity of our case with an Italian series of SARS-CoV2 cases [21], and (vi) epidemiologic evidence of myopathogenicity in SARS-CoV2 infection [1,2,3].

In conclusion, we want to stress the possible myotoxic effect of SARS-CoV2 that should be carefully assessed particularly in severe SARS-CoV2 infection. In addition, it merits exploring, whether serum CPK is a potential prognostic indicator for muscle weakness and prolonged mechanical ventilation.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Abbreviations

CPK:

Serum creatinine phosphokinase

EMG:

Electromyogram

ARDS:

Acute respiratory distress syndrome

MV:

Mechanical ventilation

MRI:

Magnetic resonance imaging

GBS:

Guillain-Barré syndrome

AMAN:

Acute Motor Axonal Neuropathy

ICU:

Intensive care unit

PT:

Prothrombin time

aPTT:

Activated partial thromboplastin time

SGPT:

Serum glutamic pyruvic transaminase

BNP:

Brain natriuretic peptide

WBC:

White blood cells

CS:

Culture and sensitivity

MRSA:

Methicillin-resistant Staphylococcus aureus

dCMAP:

Distal Compound Muscle Action Potential

CIP:

Critical illness polyneuropathy

CIM:

Critical illness myopathy

References

  1. 1.

    Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020;77(6):683–90. https://doi.org/10.1001/jamaneurol.2020.1127.

    Article  PubMed  Google Scholar 

  2. 2.

    Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020;94(22):959–69. https://doi.org/10.1212/WNL.0000000000009566.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Madia F, Merico B, Primiano G, Cutuli SL, De Pascale G, Servidei S. Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Neurology. 2020;95(11):492–4. https://doi.org/10.1212/WNL.0000000000010280.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Leung TW, Wong KS, Hui AC, To KF, Lai ST, Ng WF, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Archiv Neurol. 2005;62(7):1113–7. https://doi.org/10.1001/archneur.62.7.1113.

    Article  Google Scholar 

  5. 5.

    Tsai LK, Hsieh ST, Chao CCm, Chen YC, Lin YH, Chang SC, Chang YC Neuromuscular disorders in severe acute respiratory syndrome. Archives of neurology 2004; 61(11): 1669-1673, DOI: https://doi.org/10.1001/archneur.61.11.1669.

  6. 6.

    Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–94. https://doi.org/10.1056/NEJMoa030685.

    Article  Google Scholar 

  7. 7.

    Lacomis D. Electrophysiology of neuromuscular disorders in critical illness. Muscle & nerve. 2013;47(3):452–63. https://doi.org/10.1002/mus.23615.

    Article  Google Scholar 

  8. 8.

    Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19(5):383–4. https://doi.org/10.1016/S1474-4422(20)30109-5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré syndrome associated with SARS-CoV-2. The New England journal of medicine. 2020;382(26):2574–6. https://doi.org/10.1056/NEJMc2009191.

    Article  PubMed  Google Scholar 

  10. 10.

    Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. Journal of the peripheral nervous system : JPNS. 2020;25(2):204–7. https://doi.org/10.1111/jns.12382.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–9. https://doi.org/10.1016/S0140-6736(16)00562-6.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, Herbrink P, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology. 2010;74(7):581–7. https://doi.org/10.1212/WNL.0b013e3181cff735.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Williams S, Horrocks IA, Ouvrier RA, Gillis J, Ryan MM. Critical illness polyneuropathy and myopathy in pediatric intensive care: a review. Pediatr Crit Care Med. 2007 Jan;8(1):18–22. https://doi.org/10.1097/01.pcc.0000256623.01254.40.

    Article  PubMed  Google Scholar 

  14. 14.

    Z’Graggen WJ, Schefold JC. Critical illness myopathy: glucocorticoids revisited? Acta physiologica (Oxford, England). 2019;225(2):e13205.

    Article  Google Scholar 

  15. 15.

    Akkad H, Cacciani N, Llano-Diez M, et al. Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model. Acta physiologica (Oxford, England). 2019;225(2):e13172.

    Article  Google Scholar 

  16. 16.

    Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clinical microbiology reviews. 2008;21(3):473–94. https://doi.org/10.1128/CMR.00001-08.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014;178(3):405–15. https://doi.org/10.1111/cei.12445.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & growth factor reviews. 2020;53:25–32. https://doi.org/10.1016/j.cytogfr.2020.05.003.

    CAS  Article  Google Scholar 

  19. 19.

    Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. Journal of neurology. 2001;248(11):929–34. https://doi.org/10.1007/s004150170043.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Shepherd S, Batra A, Lerner DP. Review of critical illness myopathy and neuropathy. The Neurohospitalist. 2017;7(1):41–8. https://doi.org/10.1177/1941874416663279.

    Article  PubMed  Google Scholar 

  21. 21.

    Madia F, Merico B, Primiano G, Cutuli SL, De Pascale G, Servidei S. Acute myopathic quadriplegia in COVID-19 patients in the intensive care unit. Neurology. 2020;95(11):492–4. https://doi.org/10.1212/WNL.0000000000010280.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the contribution of icddr,b’s core donors including the governments of Bangladesh, Canada, Sweden, and the UK for their continuous support and commitment to icddr,b’s research efforts.

Funding

This research activity was not funded.

Author information

Affiliations

Authors

Contributions

BI has written the manuscript and performed the nerve electrophysiology, MA has treated the patient in the ICU, ZI has performed the Anti GM1 antibody test, SMB has performed the muscle histopathology. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Badrul Islam.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethics committees of the International Center for Diarrhoeal Disease Research, Bangladesh and Bangladesh Specialized Hospital, Bangladesh.

Consent for publication

The patient’s wife gave written informed consent on behalf of the patient (as the patient was unable to sign due to weakness).

Competing interests

No authors have financial, professional, or personal conflict of interest that may influence this manuscript to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Islam, B., Ahmed, M., Islam, Z. et al. Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature. Skeletal Muscle 11, 10 (2021). https://doi.org/10.1186/s13395-021-00266-5

Download citation

Keywords

  • Myopathy
  • Guillain-Barré syndrome
  • Nerve conduction
  • Electromyogram
  • SARS-CoV2